|
|||||
![]() |
|
Healthcare apparel company Figs (NYSE:FIGS) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $124.9 million. Its non-GAAP loss of $0 per share decreased from $0.01 in the same quarter last year.
Is now the time to buy FIGS? Find out in our full research report (it’s free).
Figs’ first quarter results reflected a return to positive growth in the U.S. and an uptick in average order value, as management emphasized normalization in healthcare apparel purchasing patterns. CEO Trina Spear noted, “We saw continued signs that scrubwear trends are starting to normalize from the COVID overhang,” highlighting stronger gains during standard pricing periods and improved customer retention. The company also attributed performance to successful customer reactivation campaigns and increased full-price sales, resulting in record average order values. International sales maintained momentum, and non-scrubwear items like footwear and underscrubs experienced double-digit growth. Management pointed to disciplined marketing and inventory strategies, along with ongoing investments in fulfillment and supply chain operations, as key contributors to the quarter’s outcomes.
Looking ahead, management’s outlook centers on mitigating the impact of newly imposed tariffs and adapting to ongoing macroeconomic uncertainty. CFO Sarah Oughtred stated, “Our full year adjusted EBITDA outlook assumes the current 10% baseline and reciprocal tariffs on China remain in effect,” while emphasizing the company’s focus on cost mitigation and selective investments in international expansion, business-to-business (B2B) sales, and retail stores. CEO Trina Spear indicated continued commitment to cautious promotional strategies and a deliberate approach to potential pricing actions, noting, “We’re focused on doing everything we can to offset the impact of the tariffs.” Management expects gross margins to remain stable in the near term, but anticipates higher cost pressures in the second half of the year as tariff effects flow through inventory. Figs plans to prioritize operational discipline while maintaining investments in growth initiatives.
Management identified a rebound in U.S. demand, improved customer engagement, and ongoing supply chain investments as primary drivers of quarterly performance, while also outlining challenges from tariffs and evolving promotional strategies.
Figs’ guidance for the remainder of the year is shaped by ongoing tariff exposure, evolving promotional tactics, and continued investment in growth channels.
In upcoming quarters, the StockStory team will focus on (1) the pace and success of international expansion, including new market entries in Japan and South Korea, (2) the effectiveness of cost mitigation efforts as tariff pressures build in the second half of the year, and (3) progress in scaling the B2B TEAMS business and physical retail footprint. Additional attention will be paid to customer retention metrics and the impact of evolving promotional strategies.
Figs currently trades at a forward P/E ratio of 67.2×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
Jun-10 | |
Jun-04 | |
May-09 | |
May-09 | |
May-09 | |
May-08 | |
May-08 | |
May-08 | |
May-08 | |
May-08 | |
May-07 | |
May-07 | |
May-05 | |
May-02 | |
Apr-30 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite